EN IT

Targeting unmet needs in personalized oncology

XEPTAGEN SpA is engaged in the discovery and validation of novel molecular markers to improve the clinical management of cancer patients by creating innovative diagnostic tools that may allow a personalized treatment.

Latest Product Literature

Clinical validation of the iXip index in avoiding unnecessary prostate biopsy: results from a prospective multicenter study involving 426 patients. Cancer Treat Res Comm. 10:40-45. 2017.

Serum and bile squamous cell carcinoma antigen 1 (SCCA1) detection: a new diagnostic approach in patients with perihilar cholangiocarcinoma (pCCA). The Liver Meeting-American Association for the Study of Liver Diseases (AASLD). Washington DC, USA. 2017.

Circulating SCCA-IgM complex is a useful biomarker to predict the outcome of therapy in hepatocellular carcinoma patients. Scand J Clin Lab Invest. 77(6):448-453. 2017.

Squamous Cellular Carcinoma Antigen serum determination as a biomarker of Barrett esophagus and esophageal cancer: a phase III study. J. Clin. Gastroenterol.. E-pub ahead of print. 2017.

In HCV infected patients with cirrhosis Squamous Cell Carcinoma Antigen (SCCA)-IgM levels may contribute to identify the individual risk of HCC development after antiviral therapy. Dig Liver Dis. 49S:e48. 2017.

Squamous Cell Carcinoma Antigen-Immunoglobulin M (SCCA-IgM) as biomarker in liver disease: biological aspects and clinical applications. Biom Liver Dis. 1-22. 2016.


Press Releases

RSS Feed Widget

Youtube

Tweets by Xeptagen